404 documents

Read All
22:01 , Jul 19, 2019 |  BioCentury  |  Product Development

Gilead’s $5.1B Galapagos deal threads the needle between M&A and licensing

The structure of Gilead’s partnership with Galapagos gives the U.S. biotech access to all of Galapagos’ programs, without the brain drain that followed its acquisition of Kite. Human capital was the driver behind Gilead Sciences...
Read More
15:06 , Jul 15, 2019 |  BC Extra  |  Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD, and ensures its independence into the next decade. Under the...
Read More
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
Read More
21:56 , Jun 28, 2019 |  BC Extra  |  Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
Read More
21:29 , Jun 21, 2019 |  BioCentury  |  Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders' topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren't eligible for biologics. Frazier Healthcare launched the company in 2016...
Read More
00:09 , Jun 4, 2019 |  BC Innovations  |  Distillery Techniques

Gemcitabine, Jevtana and Jakavi identified to treat pediatric AML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified gemcitabine, Jevtana cabazitaxel and Jakavi ruxolitinib as drugs that could help treat pediatric AML. High throughput screening of a library of...
Read More
21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
Read More
22:42 , May 15, 2019 |  BC Extra  |  Clinical News

May 15 Clinical Quick Takes: Principia, Agios, Y-mAbs, Pfizer

Principia gets $30M from Sanofi for Phase IIb MS trial start  Principia Biopharma Inc. (NASDAQ:PRNB) said partner Sanofi (Euronext:SAN; NASDAQ:SNY) began a Phase IIb trial of SAR442168 to treat relapsing multiple sclerosis, triggering a $30...
Read More
23:55 , Mar 28, 2019 |  BC Extra  |  Clinical News

Filgotinib hits more RA endpoints

Gilead and Galapagos took a step closer to submitting regulatory applications for filgotinib to treat rheumatoid arthritis after the partners reported positive data from the two remaining Phase III trials of the oral Janus kinase-1...
Read More
19:15 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

FDA issues handful of new PDUFA dates

With the government shutdown resolved, FDA has accepted a handful of applications for review during the beginning Feb. 18, according to company announcements. FDA granted Priority Review to two applications from Genentech Inc. for entrectinib...
Read More